International Clinical Neuroscience Journal

Vol. 5 No. 3 (2018)

Secondary Brain Lymphoma in a Case of Breast Diffused Large B-Cell Lymphoma: Case Report

International Clinical Neuroscience Journal, Vol. 5 No. 3 (2018), 30 Mehr 2018 , Page 113-114

Abstract

Secondary central nervous system lymphoma (SCNSL) is known as a rare disease. The risk factor of developing SCNSL is primary lymphoma type and site of involvement. We present a patient with an altered mental status known case of breast diffused large B-cell lymphoma (DLBCL) who underwent stereotactic biopsy because of a left periventricular mass lesion, which diagnosed as secondary brain lymphoma after pathologic typing. Because of limited data about the secondary central nervous system, lymphoma and it is a risk factor, we reported an aggressive breast DLBCL with brain involvement.

How to Cite

1.
Javadian H, Jalili Khoshnood R, Shahmohammadi MR, Hosseini SAH, Keikhaee M. Secondary Brain Lymphoma in a Case of Breast Diffused Large B-Cell Lymphoma: Case Report. Int Clin Neurosci J [Internet]. 2018 Sep. 30 [cited 2023 Dec. 1];5(3):113-4. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/23399

References

Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol. 2006;84(2):128-35. doi: 10.1532/ijh97.06091.

Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large- B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-33.

van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008;49 Suppl 1:52-8. doi: 10.1080/10428190802311458.

Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011;12(13):1258-66. doi: 10.1016/s1470-2045(11)70140-1.

Roth P, Martus P, Kiewe P, Mohle R, Klasen H, Rauch M, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79(9):890-6. doi: 10.1212/WNL.0b013e318266fcb2.

Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin’s lymphoma: a review of the literature. Semin Neurol. 2004;24(4):395-404. doi: 10.1055/s-2004-861534.

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High- Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-57. doi: 10.1093/annonc/ mdl327.

  • Abstract Viewed: 361 times
  • PDF Downloaded: 291 times

Download Statastics